{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:34:59Z","timestamp":1792794899740,"version":"4.5.0"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T00:00:00Z","timestamp":1647216000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Mayo Clinic Foundation and the Department of Laboratory Medicine and Pathology","id":[{"id":"https:\/\/ror.org\/02qp3tb03","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,12,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To investigate immune-mediated necrotizing myopathy (IMNM) association with cancer and its clinical implications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>IMNM cases were identified 1 January 2000 to 31 December 2020 matching sex and age controls (4:1).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 152 patients with IMNM were identified and among serologically tested, 60% (83\/140) were HMGCR-IgG+, 14% (20\/140) were SRP-IgG+ and 26% (37\/140) were seronegative. Cancer rates were not significantly different between serological subgroups; 18.1% (15\/83) HMGCR-IgG+, 25% (5\/20) SRP-IgG+ and 30% (11\/37) seronegative (P\u2009=\u20090.34). Cancer screening was performed within 12\u2009months from IMNM diagnosis in 88% (134\/152) (whole-body CT plus FDG-PET CT in 53, CT alone in 72 and FDG-PET alone in 9). FDG-PET\/CT was positive in 73% (25\/34) of cancers. Increasing age was the only risk associated with cancer (P\u2009=\u20090.02). The odds of developing cancer at \u00b13 or \u00b15\u2009years from IMNM diagnosis was not higher than controls (OR\u2009=\u20090.49; CI: 0.325\u20130.76). Lifetime IMNM diagnosis of cancer was less compared with controls (OR\u2009=\u20090.5 CI: 0.33\u20130.78, P\u2009=\u20090.002). Most patients responded to treatment (137\/147, P\u2009&amp;lt;\u20090.001). Death and treatment response did not significantly differ between cancer [23% (8\/34); 88% (29\/33)] and non-cancer patients [19% (23\/118); 92% (108\/118)]. In total, 13% (20\/152) of patients died during follow-up compared with 14% (41\/290) of medicine and 16% (46\/290) of neurology controls (P\u2009=\u20090.8). Seropositives had greater life expectancy than seronegatives (P\u2009=\u20090.01).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Greater cancer risk is not observed in IMNM vs controls. Cancer screening in IMNM should be individualized based on age-personal and family history, including consideration of FDG-PET\/CT. Immune-treatment response did not differ with cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/keac144","type":"journal-article","created":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T15:10:54Z","timestamp":1647011454000},"page":"281-289","source":"Crossref","is-referenced-by-count":23,"title":["Cancer and immune-mediated necrotizing myopathy: a longitudinal referral case-controlled outcomes evaluation"],"prefix":"10.1093","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3585-1687","authenticated-orcid":false,"given":"Shahar","family":"Shelly","sequence":"first","affiliation":[{"name":"Department of Neurology, Mayo Clinic , Rochester, MN, USA"},{"name":"Sheba Medical Center, Department of Neurology, Sackler School of Medicine , Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3512-1796","authenticated-orcid":false,"given":"Grayson","family":"Beecher","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mayo Clinic , Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margherita","family":"Milone","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mayo Clinic , Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0212-5697","authenticated-orcid":false,"given":"Teerin","family":"Liewluck","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mayo Clinic , Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Floranne","family":"Ernste","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Mayo Clinic , Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Triplett","sequence":"additional","affiliation":[{"name":"Department of Neurology, Concord Repatriation General Hospital , Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6212-1236","authenticated-orcid":false,"given":"Elie","family":"Naddaf","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mayo Clinic , Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Zekeridou","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mayo Clinic , Rochester, MN, USA"},{"name":"Department of Laboratory Medicine and Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"McKeon","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mayo Clinic , Rochester, MN, USA"},{"name":"Department of Laboratory Medicine and Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6140-5584","authenticated-orcid":false,"given":"Sean J","family":"Pittock","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mayo Clinic , Rochester, MN, USA"},{"name":"Department of Laboratory Medicine and Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divyanshu","family":"Dubey","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mayo Clinic , Rochester, MN, USA"},{"name":"Department of Laboratory Medicine and Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R","family":"Mills","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Mandrekar","sequence":"additional","affiliation":[{"name":"Department of Quantitative Health Sciences and Biostatistics, Mayo Clinic , Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J","family":"Klein","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mayo Clinic , Rochester, MN, USA"},{"name":"Department of Laboratory Medicine and Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,3,14]]},"reference":[{"key":"2022122410015338900_keac144-B1","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1093\/brain\/aww054","article-title":"High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody","volume":"139","author":"Allenbach","year":"2016","journal-title":"Brain"},{"key":"2022122410015338900_keac144-B2","doi-asserted-by":"crossref","first-page":"e290","DOI":"10.1212\/NXI.0000000000000290","article-title":"Cancer association as a risk factor for anti-HMGCR antibody-positive myopathy","volume":"3","author":"Kadoya","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2022122410015338900_keac144-B3","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/mus.24541","article-title":"Clinical and genetic associations of autoantibodies to 3-hydroxy-3-methyl-glutaryl-coenzyme a reductase in patients with immune-mediated myositis and necrotizing myopathy","volume":"52","author":"Limaye","year":"2015","journal-title":"Muscle Nerve"},{"key":"2022122410015338900_keac144-B4","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1001\/jamaneurol.2015.1207","article-title":"Clinical features and treatment outcomes of necrotizing autoimmune myopathy","volume":"72","author":"Kassardjian","year":"2015","journal-title":"JAMA Neurol"},{"key":"2022122410015338900_keac144-B5","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1136\/jnnp.33.3.398","article-title":"Necrosis of muscle with carcinoma: myositis or myopathy?","volume":"33","author":"Urich","year":"1970","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2022122410015338900_keac144-B6","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/BF00328515","article-title":"Paraneoplastic necrotizing myopathy: a rare disorder to be differentiated from polymyositis","volume":"236","author":"Vosskamper","year":"1989","journal-title":"J Neurol"},{"key":"2022122410015338900_keac144-B7","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1212\/WNL.41.6.936","article-title":"Necrotizing myopathy with pipestem capillaries, microvascular deposition of the complement membrane attack complex (MAC), and minimal cellular infiltration","volume":"41","author":"Emslie-Smith","year":"1991","journal-title":"Neurology"},{"key":"2022122410015338900_keac144-B8","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1093\/rheumatology\/keab166","article-title":"A systematic review and meta-analysis to inform cancer screening guidelines in idiopathic inflammatory myopathies","volume":"60","author":"Oldroyd","year":"2021","journal-title":"Rheumatology"},{"key":"2022122410015338900_keac144-B9","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.nmd.2017.09.016","article-title":"Immune-Mediated Necrotizing Myopathies Working G. 224th ENMC International Workshop: clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14-16 October 2016","volume":"28","author":"Allenbach","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"2022122410015338900_keac144-B10","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13075-019-2093-6","article-title":"Statin-induced anti-HMGCR myopathy: successful therapeutic strategies for corticosteroid-free remission in 55 patients","volume":"22","author":"Meyer","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"2022122410015338900_keac144-B11","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1080\/03009742.2019.1672782","article-title":"Anti-hydroxy-3-methylglutaryl-coenzyme A reductase (anti-HMGCR) antibody in necrotizing myopathy: treatment outcomes, cancer risk, and role of autoantibody level","volume":"49","author":"Aggarwal","year":"2020","journal-title":"Scand J Rheumatol"},{"key":"2022122410015338900_keac144-B12","first-page":"787","article-title":"More severe disease and slower recovery in younger patients with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy","volume":"56","author":"Tiniakou","year":"2017","journal-title":"Rheumatology"},{"key":"2022122410015338900_keac144-B13","doi-asserted-by":"crossref","first-page":"670784","DOI":"10.3389\/fneur.2021.670784","article-title":"The clinicopathological distinction between seropositive and seronegative immune-mediated necrotizing myopathy in China","volume":"12","author":"Ma","year":"2021","journal-title":"Front Neurol"},{"key":"2022122410015338900_keac144-B14","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.amjmed.2009.11.012","article-title":"Conventional cancer screening versus PET\/CT in dermatomyositis\/polymyositis","volume":"123","author":"Selva-O'Callaghan","year":"2010","journal-title":"Am J Med"},{"key":"2022122410015338900_keac144-B15","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1097\/BOR.0000000000000535","article-title":"The diagnostic work-up of cancer-associated myositis","volume":"30","author":"Selva-O'Callaghan","year":"2018","journal-title":"Curr Opin Rheumatol"},{"key":"2022122410015338900_keac144-B16","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.mayocp.2015.07.011","article-title":"Answers to common questions about the use and safety of CT scans","volume":"90","author":"McCollough","year":"2015","journal-title":"Mayo Clin Proc"},{"key":"2022122410015338900_keac144-B17","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1088\/0952-4746\/34\/1\/E1","article-title":"Risks from CT scans\u2013what do recent studies tell us?","volume":"34","author":"Walsh","year":"2014","journal-title":"J Radiol Prot"},{"key":"2022122410015338900_keac144-B18","doi-asserted-by":"crossref","first-page":"f2360","DOI":"10.1136\/bmj.f2360","article-title":"Cancer risk in 680,000 people exposed to computed tomography scans in childhood or adolescence: data linkage study of 11 million Australians","volume":"346","author":"Mathews","year":"2013","journal-title":"BMJ"},{"key":"2022122410015338900_keac144-B19","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/ije\/dyx268","article-title":"Data Resource Profile: expansion of the Rochester Epidemiology Project medical records-linkage system (E-REP)","volume":"47","author":"Rocca","year":"2018","journal-title":"Int J Epidemiol"},{"key":"2022122410015338900_keac144-B20","doi-asserted-by":"crossref","first-page":"fcaa191","DOI":"10.1093\/braincomms\/fcaa191","article-title":"Diagnostic modelling and therapeutic monitoring of immune-mediated necrotizing myopathy: role of electrical myotonia","volume":"2","author":"Triplett","year":"2020","journal-title":"Brain Commun"},{"key":"2022122410015338900_keac144-B21","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1085-9489.2005.0010206.x","article-title":"History of standard scoring, notation, and summation of neuromuscular signs. A current survey and recommendation","volume":"10","author":"Dyck","year":"2005","journal-title":"J Peripher Nerv Syst"},{"key":"2022122410015338900_keac144-B22","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.nmd.2014.12.001","article-title":"205th ENMC International Workshop: pathology diagnosis of idiopathic inflammatory myopathies part II 28-30 March 2014, Naarden, The Netherlands","volume":"25","author":"De Bleecker","year":"2015","journal-title":"Neuromuscul Disord"},{"key":"2022122410015338900_keac144-B23","author":"Statistics NCfH"},{"key":"2022122410015338900_keac144-B24","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1136\/jnnp.2003.034447","article-title":"Recommended diagnostic criteria for paraneoplastic neurological syndromes","volume":"75","author":"Graus","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2022122410015338900_keac144-B25","volume-title":"StatPearls","author":"Thapa","year":"2021"},{"key":"2022122410015338900_keac144-B26","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/aje\/kwq433","article-title":"Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries","volume":"173","author":"Quan","year":"2011","journal-title":"Am J Epidemiol"},{"key":"2022122410015338900_keac144-B27","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"2022122410015338900_keac144-B28","doi-asserted-by":"crossref","first-page":"e1014","DOI":"10.1212\/NXI.0000000000001014","article-title":"Updated diagnostic criteria for paraneoplastic neurologic syndromes","volume":"8","author":"Graus","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2022122410015338900_keac144-B29","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1212\/WNL.26.7.696","article-title":"Recurrence of thymoma and myasthenia gravis after 19 years. A case report","volume":"26","author":"Lava","year":"1976","journal-title":"Neurology"},{"key":"2022122410015338900_keac144-B30","first-page":"362","article-title":"Paraneoplastic neurological syndrome: an evolving story","volume":"8","author":"Jitprapaikulsan","year":"2021","journal-title":"Neurooncol Pract"},{"key":"2022122410015338900_keac144-B31","volume-title":"Diagnosing and treating adult cancers and associated impairments","author":"National Academies of Sciences Engineering, and Medicine","year":"2021"},{"key":"2022122410015338900_keac144-B32","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/MD.0000000000000028","article-title":"Anti-HMGCR autoantibodies in European patients with autoimmune necrotizing myopathies: inconstant exposure to statin","volume":"93","author":"Allenbach","year":"2014","journal-title":"Medicine"},{"key":"2022122410015338900_keac144-B33","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/s41584-020-00515-9","article-title":"Immune-mediated necrotizing myopathy: clinical features and pathogenesis","volume":"16","author":"Allenbach","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"2022122410015338900_keac144-B34","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s10067-005-1164-z","article-title":"Prognosis and mortality of polymyositis and dermatomyositis patients","volume":"25","author":"Airio","year":"2006","journal-title":"Clin Rheumatol"},{"key":"2022122410015338900_keac144-B35","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1016\/j.mayocp.2020.03.032","article-title":"Cardiac and respiratory complications of necrotizing autoimmune myopathy","volume":"95","author":"Triplett","year":"2020","journal-title":"Mayo Clin Proc"},{"key":"2022122410015338900_keac144-B36","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1001\/jama.2020.9151","article-title":"Immortal time bias in observational studies","volume":"325","author":"Yadav","year":"2021","journal-title":"JAMA"},{"key":"2022122410015338900_keac144-B37","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1002\/acr.21671","article-title":"Increased frequency of DRB111:01 in anti-hydroxymethylglutaryl-coenzyme A reductase-associated autoimmune myopathy","volume":"64","author":"Mammen","year":"2012","journal-title":"Arthritis Care Res"},{"key":"2022122410015338900_keac144-B38","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1161\/JAHA.116.005449","article-title":"Vulnerabilities to health disparities and statin use in the REGARDS (Reasons for Geographic and Racial Differences in Stroke) study","volume":"6","author":"Schroff","year":"2017","journal-title":"J Am Heart Assoc"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keac144\/42981229\/keac144.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/62\/1\/281\/48404631\/keac144.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/62\/1\/281\/48404631\/keac144.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T23:58:54Z","timestamp":1726790334000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/62\/1\/281\/6548157"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,14]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,3,14]]},"published-print":{"date-parts":[[2022,12,23]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keac144","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,1,1]]},"published":{"date-parts":[[2022,3,14]]}}}